© 2024 MICHIGAN PUBLIC
91.7 Ann Arbor/Detroit 104.1 Grand Rapids 91.3 Port Huron 89.7 Lansing 91.1 Flint
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

Success story for cystic fibrosis treatment has downside

A new study says aggressively treating lung infections in cystic fibrosis patients works – but only for awhile. 

Dr. John LiPuma of the University of Michigan says people with C-F live longer, healthier lives now because of antibiotics. 

But, after a while, the drugs kill off more benign bacteria.  That allows drug-resistent bacteria to flourish. 

Eventually, there’s nothing doctors can do for their C-F patients who develop bacterial lung infections.

Says LiPuma:  "What we’re learning is that manipulating the complex community of bacteria in a more thoughtful, and deliberate and clever way may be a better strategy to what we’ve been doing -- which has been to try to eliminate all the bacteria in the lung."

LiPuma says the alternative is to develop more antibiotics that only kill some bacteria, allowing other, less harmful ones to survive.

LiPuma is involved in the Human Microbiome Project, which is investigating how to maximize the benefit of so-called “good,” microbes, while suppressing the harm from “bad” microbes.

 

 

Tracy Samilton covers energy and transportation, including the auto industry and the business response to climate change for Michigan Public. She began her career at Michigan Public as an intern, where she was promptly “bitten by the radio bug,” and never recovered.